Literature DB >> 22542031

Evaluating the risk of transmission of infection from donor to recipient of a solid organ transplantation.

Óscar Len1, Antonio Ramos, Albert Pahissa.   

Abstract

In the context of solid organ transplantation, screening of potential organ donors is crucial, and should be performed with great rigor to minimize the risk of transmission of certain infectious processes. This review aims to update understanding of the possible pathologies involved, as well as of emerging infections that, as a result of globalization, are gaining increasing prominence on a daily basis.
Copyright © 2012 Elsevier España S.L. All rights reserved.

Entities:  

Mesh：

Year:  2012        PMID： 22542031      PMCID： PMC7130295          DOI： 10.1016/S0213-005X(12)70078-2

Source DB:  PubMed          Journal:  Enferm Infecc Microbiol Clin        ISSN： 0213-005X            Impact factor:   1.731


  49 in total

1.  Transmission of Histoplasma capsulatum by organ transplantation.

Authors:  A P Limaye; P A Connolly; M Sagar; T R Fritsche; B T Cookson; L J Wheat; W E Stamm
Journal:  N Engl J Med       Date:  2000-10-19       Impact factor: 91.245

2.  Clinical significance of donor-unrecognized bacteremia in the outcome of solid-organ transplant recipients.

Authors:  C Lumbreras; F Sanz; A González; G Pérez; M J Ramos; J M Aguado; M Lizasoain; A Andrés; E Moreno; M A Gómez; A R Noriega
Journal:  Clin Infect Dis       Date:  2001-07-25       Impact factor: 9.079

Review 3.  Transmission of tropical and geographically restricted infections during solid-organ transplantation.

Authors:  P Martín-Dávila; J Fortún; R López-Vélez; F Norman; M Montes de Oca; P Zamarrón; M I González; A Moreno; T Pumarola; G Garrido; A Candela; S Moreno
Journal:  Clin Microbiol Rev       Date:  2008-01       Impact factor: 26.132

4.  Renal transplantation between HIV-positive donors and recipients.

Authors:  Elmi Muller; Delawir Kahn; Marc Mendelson
Journal:  N Engl J Med       Date:  2010-06-17       Impact factor: 91.245

5.  Use of renal allografts from donors positive for hepatitis B core antibody confers minimal risk for subsequent development of clinical hepatitis B virus disease.

Authors:  R M Madayag; L B Johnson; S T Bartlett; E J Schweitzer; N T Constantine; R J McCarter; P C Kuo; S Keay; D W Oldach
Journal:  Transplantation       Date:  1997-12-27       Impact factor: 4.939

6.  The risk of HIV, HBV, HCV and HTLV infection among musculoskeletal tissue donors in Australia.

Authors:  F Yao; C Seed; A Farrugia; D Morgan; S Cordner; D Wood; M H Zheng
Journal:  Am J Transplant       Date:  2007-12       Impact factor: 8.086

7.  Tuberculosis after solid-organ transplant: incidence, risk factors, and clinical characteristics in the RESITRA (Spanish Network of Infection in Transplantation) cohort.

Authors:  Julián Torre-Cisneros; Antonio Doblas; José María Aguado; Rafael San Juan; Marino Blanes; Miguel Montejo; Carlos Cervera; Oscar Len; Jordi Carratala; José Miguel Cisneros; Germán Bou; Patricia Muñoz; Antonio Ramos; Merce Gurgui; Nuria Borrell; Jesus Fortún; Asunción Moreno; Joan Gavalda
Journal:  Clin Infect Dis       Date:  2009-06-15       Impact factor: 9.079

8.  Sensitivity of two hepatitis B virus, hepatitis C virus (HCV), and human immunodeficiency virus (HIV) nucleic acid test systems relative to hepatitis B surface antigen, anti-HCV, anti-HIV, and p24/anti-HIV combination assays in seroconversion panels.

Authors:  Azzedine Assal; Valérie Barlet; Marie Deschaseaux; Isabelle Dupont; Pierre Gallian; Cathy Guitton; P Morel; Harry van Drimmelen; Bernard David; Nico Lelie; Philippe De Micco
Journal:  Transfusion       Date:  2009-02       Impact factor: 3.157

9.  Transmission of human immunodeficiency virus and hepatitis C virus through liver transplantation.

Authors:  Joseph Ahn; Stanley M Cohen
Journal:  Liver Transpl       Date:  2008-11       Impact factor: 5.799

Review 10.  Toxoplasma gondii: transmission, diagnosis and prevention.

Authors:  D Hill; J P Dubey
Journal:  Clin Microbiol Infect       Date:  2002-10       Impact factor: 8.067
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.